via UCL
Biodegradable microspheres can be used to deliver heart cells generated from stem cells to repair damaged hearts after a heart attack, according to new findings by UCL researchers
This type of cell therapy could one day cure debilitating heart failure, which affects an estimated 920,000 people in the UK and continues to rise as more people are surviving a heart attack than ever before.
Scientists have been trying to use stem cells to repair damaged hearts for a number of years. However, these cells often don’t remain in the heart in a healthy state for long enough to provide a sustained benefit.
Now, a UCL team, funded by the British Heart Foundation (BHF), has grown human stem cell-derived heart cells on tiny microspheres, each only a quarter of a millimetre wide, engineered from biological material. The cells attach to and grow on the microspheres, make connections with each other and are able to beat for up to 40 days in a dish. The small size of the microspheres means they can be easily injected into the heart muscle using a needle.
The researchers have also taken this one step further by developing state-of-the-art technology to visualise the injected microspheres and confirm they remain in place. Barium sulphate (BaSO4), which shines bright on X-rays and CT scans, was added to the microspheres and injected into rat hearts. Whole body CT scans confirmed that the microspheres remained in place for up to 6 days after injection.
The researchers say this technology could provide the next generation of materials to effectively deliver new cells to failing hearts to restore their function, and hope it will be tested in human clinical trials in the next 10 years. They presented their findings at the British Cardiovascular Society Conference.
Dr Daniel Stuckey, leader of cardiac imaging at the UCL Centre for Advanced Biomedical Imaging, said: “To truly mend broken hearts, it is important that stem cells are delivered in a way that allows them to survive within their new environment and turn into heart muscle cells. Our technology provides a new way of ensuring that the cells injected into the heart are working as they should. We hope this research will give us the information essential for making stem cell therapy a realistic treatment for people with heart disease.
PhD student Annalisa Bettini (UCL Institute of Cardiovascular Science), who led the study, said: “We can do even more with this technology – as well as developing heart injections, we are developing these traceable microspheres to act as heart patches that can be simply injected to the particular area of heart damage. In the future, these could provide cardiologists with a number of solutions to provide the best treatment for their patients.”
Professor Metin Avkiran, Associate Medical Director at the British Heart Foundation, said: “This is a promising new delivery system that could give stem cell-derived heart cells the best chance of repairing damaged hearts. After a heart attack, heart muscle tissue becomes damaged and has a limited ability to heal itself, increasing a person’s chance of developing heart failure.
“Breakthroughs like this bring us closer to finding much-needed cures for heart failure and provide light at the end of the tunnel for the hundreds of thousands of people living with this debilitating condition.”
Original Article: Injectable microspheres to repair failing hearts
More from: University College London
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Repairing damaged hearts
- Insight into how congenital heart defects manifest
In an effort to learn more about how the heart develops, researchers have determined that the cells lining the heart direct the cardiac muscle to grow until the heart reaches its full size. They also ...
- Buffalo center fuels research that can save your life from heart disease and stroke
Medical school, research center foster translational medicine, which combines disciplines, resources and techniques to move benchtop research to the patient bedside, eventually strengthening community ...
- New Technology Repairs and Regenerates Heart Cells After a Heart Attack
A "powerful clinical strategy" for treating heart disease may result from the recent discovery. University of Houston researchers have developed a groundbreaking technique that, in mice, not only rest ...
- New Study Reveals How Zebrafish Can Restore Damaged Heart
New research demonstrates how zebrafish can regenerate heart tissue after injury.The cardiomyocytes are harmed when they are oxygen-deprived during a heart attack, and chronic scarring takes ...
- Zebrafish Can Repair a Damaged Heart, And a New Study Reveals How
Zebrafish are marvelous creatures. Not only are they completely see-through, but they can also grow new organs. We already knew these translucent little fish could regenerate retinal tissue in their e ...
Go deeper with Google Headlines on:
Repairing damaged hearts
Go deeper with Bing News on:
Injectable microspheres
- Facial Injectable Market Competitive Landscape, 2022 Market Innovation with Global Trends Forecasts by 2027
Fat Injection, Polylactic Acid, followed by others like Polymethyl-methacrylate Microspheres (PMMA), Calcium Hydroxylapatite, Other Dermal Fillers). The market’s application segment includes ...
- Intraperitoneal Therapy for Peritoneal Cancer
For example, IP injection of cisplatin-loaded polymeric microspheres (100–200 µm, which releases cisplatin over 3–4 weeks) resulted in localization of microspheres and significantly higher ...
- Evidence for Human Lung Stem Cells
After injection into damaged mouse lung in vivo ... human lung stem cells mixed with 1% rhodamine-labeled polystyrene microspheres. The chests were then closed. Mice were killed at 12 hours ...
- Microspheres: Reducing Weight In Several Processes
Two Japanese firms have developed a microsphere additive technology for expanding PVC ... the technology is applicable to a wider range of processes, including injection, extrusion, and calendering, ...
- Pacira BioSciences Reports Preliminary Second Quarter 2022 Revenue of $169.4 Million
The company’s revenues include net product sales of EXPAREL ® (bupivacaine liposome injectable suspension), ZILRETTA ® (triamcinolone acetonide extended-release injectable suspension), and the ...